Sanfetrinem cilexetil
Alternative Names: GV-118819Latest Information Update: 01 Aug 2022
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antibacterials; Beta-lactams
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tuberculosis
- Discontinued Bacterial infections
Most Recent Events
- 21 Apr 2022 Phase-II clinical trials in Tuberculosis (In adults, In the elderly, Newly diagnosed) in South Africa (PO) (NCT05388448)
- 13 Dec 1999 Discontinued-II for Bacterial infections in Italy (PO)
- 31 Aug 1999 No-Development-Reported for Bacterial infections in Italy (PO)